This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 956146.

Ibrahim Ince

Scientist Systems pharmacology and Medicine, Bayer AG

(Co-)supervisor for ESR 11.

Ibrahim Ince is based at Bayer AG in Leverkusen, Germany, were he is an expert in systems pharmacology and medicine and pharmacometric leader, with experience in PBPK and Population PK-PD. He received his Master in Biopharmaceutical sciences in 2006 at the Leiden University in the Netherlands, and his PhD in Pharmacology in 2012 at the Erasmus University in Rotterdam, the Netherlands. His research interests focus in the field of infectious disease, oncology, cardiovascular disease and pediatric drug development, with particular interest in special populations. He has successfully (co-)supervised 1 PhD student and 3 master students. He is an active contributor to the field of pharmacology and biopharmaceutical sciences and has (co-)authored 11  peer reviewed papers in international journals.

Publications

  • Ince, I., Solodenko, J., Frechen, S., Dallmann, A., Niederalt, C., Schlender, J., Burghaus, R., Lippert, J. and Willmann, S. (2019) Predictive Pediatric Modeling and Simulation Using Ontogeny Information. The Journal of Clinical Pharmacology, Sep(59, Suppl 1), pp. 95-103.
  • Dallmann, A., Himstedt, A., Solodenko, J., Ince, I., Hempel, G. and Eissing, T. (2020) Integration of physiological changes during the postpartum period into a PBPK framework and prediction of amoxicillin disposition before and shortly after delivery. Journal of Pharmacokinetics and Pharmacodynamics, 47(4), pp. 341-359.
  • Dallmann, A., Solodenko, J., Ince, I. and Eissing, T. (2018) Applied Concepts in PBPK Modeling: How to Extend an Open Systems Pharmacology Model to the Special Population of Pregnant Women. Pharmacometrics and Systems Pharmacology, 7(7), pp. 419-431.
  • Dallmann, A., Ince, I., Coboeken, K., Eissing, T. and Hempel, G. (2018) A Physiologically Based Pharmacokinetic Model for Pregnant Women to Predict the Pharmacokinetics of Drugs Metabolized Via Several Enzymatic Pathways. Clinical Pharmacokinetics, 57(6), pp. 749-768.
  • Dallmann, A., Ince, I., Meyer, M., Willmann, S., Eissing, T. and Hempel, G. (2017) Gestation-Specific Changes in the Anatomy and Physiology of Healthy Pregnant Women: An Extended Repository of Model Parameters for Physiologically Based Pharmacokinetic Modeling in Pregnancy. Clinical Pharmacokinetics, 56(11), pp. 1303-1330.
  • Dallmann, A., Ince, I., Solodenko, J., Meyer, M., Willmann, S., Eissing, T. and Hempel, G. (2017) Physiologically Based Pharmacokinetic Modeling of Renally Cleared Drugs in Pregnant Women. Clinical Pharmacokinetics, 56(12), pp. 1525-1541.